T0	Interventions 139 159	amlodipine camsylate
T1	Interventions 167 186	amlodipine besylate
T2	Interventions 252 271	Amlodipine besylate
T3	Interventions 393 413	Amlodipine camsylate
T4	Interventions 740 760	amlodipine camsylate
T5	Interventions 765 784	amlodipine besylate
T6	Interventions 896 916	amlodipine camsylate
T7	Interventions 931 950	amlodipine besylate
T8	Interventions 1439 1532	randomly assigned to receive oral treatment with amlodipine camsylate or amlodipine besylate.
T9	Interventions 1533 1603	For the first 4 weeks, patients received amlodipine 5 mg QD (morning).
T10	Interventions 1604 1795	After 4 weeks, if either blood pressure was > or =140/ > or =90 mm Hg or SiDBP had not decreased by > or =10 mm Hg from baseline, the dose of amlodipine was increased to 10 mg QD for 4 weeks.
T11	Interventions 1796 2015	Trough blood pressure and heart rate were measured in duplicate with the patient in the sitting position at each clinic visit (baseline [week 0] and weeks 4 and 8 of treatment); mean values were calculated and recorded.
T12	Interventions 2016 2152	At weeks 4 and 8, tolerability was assessed using history taking and laboratory analysis, and compliance was assessed using pill counts.
T13	Interventions 2590 2610	amlodipine camsylate
T14	Interventions 2966 2986	amlodipine camsylate
T15	Interventions 2999 3019	amlodipine besylate)
T16	Interventions 3040 3060	amlodipine camsylate
T17	Interventions 3090 3109	amlodipine besylate
T18	Interventions 3288 3309	(amlodipine camsylate
T19	Interventions 3392 3411	amlodipine besylate
T20	Interventions 3878 3899	(amlodipine camsylate
T21	Interventions 3909 3928	amlodipine besylate
T22	Interventions 4044 4064	amlodipine camsylate
T23	Interventions 4069 4088	amlodipine besylate
T24	Interventions 4154 4174	amlodipine camsylate
T25	Interventions 4222 4241	amlodipine besylate